DUBLIN–(BUSINESS WIRE)–The “Drug
Addiction – Pipeline Review, H1 2019” report has been added to ResearchAndMarkets.com’s
offering.
Drug Addiction – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Drug Addiction
(Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.
The Drug Addiction (Central Nervous System) pipeline guide also reviews
of key players involved in therapeutic development for Drug Addiction
and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Filing rejected/Withdrawn, Phase
II, Phase I, Preclinical and Discovery stages are 1, 6, 9, 30 and 3
respectively. Similarly, the Universities portfolio in Phase II,
Preclinical and Discovery stages comprises 1, 13 and 3 molecules,
respectively.
Drug Addiction (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Drug Addiction (Central Nervous System). -
The pipeline guide reviews pipeline therapeutics for Drug Addiction
(Central Nervous System) by companies and universities/research
institutes based on information derived from company and
industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Drug Addiction
(Central Nervous System) therapeutics and enlists all their major and
minor projects. -
The pipeline guide evaluates Drug Addiction (Central Nervous System)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Drug Addiction (Central Nervous System)
Key Topics Covered:
- Introduction
- Drug Addiction – Overview
- Drug Addiction – Therapeutics Development
- Drug Addiction – Therapeutics Assessment
- Drug Addiction – Companies Involved in Therapeutics Development
- Drug Addiction – Drug Profiles
- Drug Addiction – Dormant Projects
- Drug Addiction – Discontinued Products
- Drug Addiction – Product Development Milestones
- Appendix
Companies Mentioned
- Addex Therapeutics Ltd
- Aelis Farma SAS
- Aphios Corp
- BioCorRx Inc
- Charleston Laboratories Inc
- Chiesi Farmaceutici SpA
- Consegna Pharma Inc
- Curemark LLC
- Denovo Biopharma LLC
- Egalet Corp
- Embera NeuroTherapeutics Inc
- F. Hoffmann-La Roche Ltd
- Foresee Pharmaceuticals Co Ltd
- IMV Inc
- InterveXion Therapeutics LLC
- Intra-Cellular Therapies Inc
- KemPharm Inc
- Kyorin Pharmaceutical Co Ltd
- Kyowa Hakko Kirin Co Ltd
- Novartis AG
- Omeros Corp
- Ovid Therapeutics Inc
- P2D Inc
- Protagenic Therapeutics Inc
- Saniona AB
- Sosei Heptares
- SpringWorks Therapeutics LLC
- Zynerba Pharmaceuticals Inc
For more information about this report visit https://www.researchandmarkets.com/r/mmge4y
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Addiction
Disorders Drugs